“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses

Title: “European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses

Volume: 9 Issue: 5

Author(s): Klaus G. Parhofer, Evangelos Liberopoulos, Matilda Florentin, Karl Winkler, Anthony S. Wierzbicki, Alexandros D. Tselepis, Gerald H. Tomkin, Giatgen A. Spinas, Giovam Battista Rini, Dimitri P. Mikhailidis, Winfried Marz, Jacqueline de Graaf, Vasilios Athyros, Alberto Zambon, Bruce Griffin, Kaspar Berneis, Manfredi Rizzo and Moses Elisaf

Affiliation:

Keywords: LDL, subclasses, atherosclerosis, cardiovascular risk, statement, hypertriglyceridaemia, coronary heart disease, cardiovascular disease, apolipoprotein, chylomicrons

Abstract: Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density lipoproteins (LDL) subclasses. We sub-divided our Statement in 2 sections: section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drugs and lifestlyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.

Cite this article as:

G. Parhofer Klaus, Liberopoulos Evangelos, Florentin Matilda, Winkler Karl, S. Wierzbicki Anthony, D. Tselepis Alexandros, H. Tomkin Gerald, A. Spinas Giatgen, Battista Rini Giovam, P. Mikhailidis Dimitri, Marz Winfried, de Graaf Jacqueline, Athyros Vasilios, Zambon Alberto, Griffin Bruce, Berneis Kaspar, Rizzo Manfredi and Elisaf Moses, “European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses, Current Vascular Pharmacology 2011; 9 (5) . https://dx.doi.org/10.2174/157016111796642661